The role of urotensin II in cardiovascular and renal physiology and diseases

British Journal of Pharmacology

Volumn 148, Issue 7, 2006, Pages 884-901

  Zhu, Yi Chun ^a,c   Zhu, Yi Zhun ^a,b   Moore, Philip Keith ^b  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c FUDAN UNIVERSITY   (China)

Author keywords

Interaction; Signalling mechanisms; Urotensin II; Urotensin receptor; Vasoactive effects

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 2 NITRO 4 CARBOXYPHENYL N,N' DIPHENYLCARBAMATE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACT 058362; INDOMETACIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE C INHIBITOR; SB 611812; SB 710411; UFP 803; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II; WORTMANNIN; G PROTEIN COUPLED RECEPTOR; UROTENSIN; UTS2R PROTEIN, HUMAN;

AORTA ARCH; BLOOD PRESSURE; CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; HEMODYNAMICS; HOMEOSTASIS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; MOLECULAR INTERACTION; NONHUMAN; ORGAN DISTRIBUTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THORACIC AORTA; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; ANIMAL; BODY FLUID; CARDIOVASCULAR FUNCTION; DRUG EFFECT; HEART; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BODY FLUIDS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; HEART; HOMEOSTASIS; HUMANS; KIDNEY; KIDNEY DISEASES; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UROTENSINS;

EID: 33749371071     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706800     Document Type: Review

References (99)

1. AIYAR, N., GUIDA, B., AO, Z., DISA, J., NASELSKY, D., BEHM, D.J., SU, J.L., KULL JR., F.C. & DOUGLAS, S.A. (2004). Differential levels of 'urotensin-II-like' activity determined by radio-receptor and radioimmuno-assays. Peptides, 25, 1339-1347.
2. AMES, R.S., SARAU, H.M., CHAMBERS, J.K., WILLETTE, R.N., AIYAR, N.V., ROMANIC, A.M., LOUDEN, C.S., FOLEY, J.J., SAUERMELCH, C.F., COATNEY, R.W., AO, Z., DISA, J., HOLMES, S.D., STADEL, J.M., MARTIN, J.D., LIU, W.S., GLOVER, G.I., WILSON, S., MCNULTY, D.E., ELLIS, C.E., ELSHOURBAGY, N.A., SHABON, U., TRILL, J.J., HAY, D.W., OHLSTEIN, E.H., BERGSMA, D.J. & DOUGLAS, S.A. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
3. BALMENT, R.J., SONG, W. & ASHTON, N. (2005). Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. Ann. NY Acad. Sci., 1040, 66-73.
4. BEHM, D.J., DOE, C.P., JOHNS, D.G., MANISCALCO, K., STANKUS, G.P., WIBBERLEY, A., WILLETTE, R.N. & DOUGLAS, S.A. (2004). Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch. Pharmacol., 369, 274-280.
5. BEHM, D.J., HEROLD, C.L., OHLSTEIN, E.H., KNIGHT, S.D., DHANAK, D. & DOUGLAS, S.A. (2002). Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br. J. Pharmacol., 137, 449-458.
6. BENNETT, R.T., JONES, R.D., MORICE, A.H., SMITH, C.F. & COWEN, M.E. (2004). Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries. Thorax, 59, 401-407.
7. BOHM, F. & PERNOW, J. (2002). Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol., 135, 25-27.
8. BOTTRILL, F.E., DOUGLAS, S.A., HILEY, C.R. & WHITE, R. (2000). Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol., 130, 1865-1870.
9. BOUSETTE, N., PATEL, L., DOUGLAS, S.A., OHLSTEIN, E.H. & GIAID, A. (2004). Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis, 176, 117-123.
10. CAMARDA, V., GUERRINI, R., KOSTENIS, E., RIZZI, A., CALO, G., HATTENBERGER, A., ZUCCHINI, M., SALVADORI, S. & REGOLI, D. (2002). A new ligand for the urotensin II receptor. Br. J. Pharmacol., 137, 311-314.
11. CAMARDA, V., SONG, W., MARZOLA, E., SPAGNOL, M., GUERRINI, R., SALVADORI, S., REGOLI, D., THOMPSON, J.P., ROWBOTHAM, D.J., BEHM, D.J., DOUGLAS, S.A., CALO, G. & LAMBERT, D.G. (2004). Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur. J. Pharmacol., 498, 83-86.
12. CAMARDA, V., SPAGNOL, M., SONG, W., VERGURA, R., ROTH, A.L., THOMPSON, J.P., ROWBOTHAM, D.J., GUERRINI, R., MARZOLA, E., SALVADORI, S., CAVANNI, P., REGOLI, D., DOUGLAS, S.A., LAMBERT, D.G. & CALÒ, G. (2006). In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). Br. J. Pharmacol., 147, 92-100.
13. CHARLES, C.J., RADEMAKER, M.T., RICHARDS, A.M. & YANDLE, T.G. (2005). Urotensin II: evidence for cardiac, hepatic and renal production. Peptides, 2611, 2211-2214.
14. CHEUNG, B.M., LEUNG, R., MAN, Y.B. & WONG, L.Y. (2004). Plasma concentration of urotensin II is raised in hypertension. J. Hypertens., 22, 1341-1344.
15. CLOZEL, M., BINKERT, C., BIRKER-ROBACZEWSKA, M., BOUKHADRA, C., DING, S.S., FISCHLI, W., HESS, P., MATHYS, B., MORRISON, K., MÜLLER, C., MÜLLER, C., NAYLER, O., QIU, C.B., REY, M., SCHERZ, M.W., VELKER, J., WELLER, T., XI, J.F. & ZILTENER, P. (2004). Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin- 1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther., 311, 204-212.
16. CLOZEL, M., HESS, P., QIU, C.B., DING, S.S. & REY, M. (2006). The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J. Pharmacol. Exp. Ther., 316, 1115-1121.
17. CONLON, J.M., YANO, K., WAUGH, D. & HAZON, N. (1996). Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J. Exp. Zool., 275, 226-238.
18. COULOUARN, Y., LIHRMANN, I., JEGOU, S., ANOUAR, Y., TOSTIVINT, H., BEAUVILLAIN, J.C., CONLON, J.M., BERN, H.A. & VAUDRY, H. (1998). Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A., 95, 15803-15808.
19. COWLEY, E., THOMPSON, J.P., SHARPE, P., WAUGH, J., ALI I, N. & LAMBERT, D.G. (2005). Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study. Br. J. Anaesth., 95, 495-499.
20. DISA, J., FLOYD, L.E., EDWARDS, R.M., DOUGLAS, S.A. & AIYAR, N.V. (2006). Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography. Peptides (in press).
21. DJORDJEVIC, T., BELAIBA, R.S., BONELLO, S., PFEILSCHIFTER, J., HESS, J. & GORLACH, A. (2005). Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 25, 519-525.
22. DOGGRELL, S.A. (2003). The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert. Opin. Invest. Drugs, 12, 805-823.
23. DOUGLAS, S.A., BEHM, D.J., AIYAR, N.V., NASELSKY, D., DISA, J., BROOKS, D.P., OHLSTEIN, E.H., GLEASON, J.G., SARAU, H.M., FOLEY, J.J., BUCKLEY, P.T., SCHMIDT, D.B., WIXTED, W.E., WIDDOWSON, K., RILEY, G., JIN, J., GALLAGHER, T.F., SCHMIDT, S.J., RIDGERS, L., CHRISTMANN, L.T., KEENAN, R.M., KNIGHT, S.D. & DHANAK, D. (2005). Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br. J. Pharmacol., 145, 620-635.
24. DOUGLAS, S.A., DHANAK, D. & JOHNS, D.G. (2004). From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol. Sci., 25, 76-85.
25. DOUGLAS, S.A., SULPIZIO, A.C., PIERCY, V., SARAU, H.M., AMES, R.S., AIYAR, N.V., OHLSTEIN, E.H. & WILLETTE, R.N. (2000). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol., 131, 1262-1274.
26. DOUGLAS, S.A., TAYARA, L., OHLSTEIN, E.H., HALAWA, N. & GIAID, A. (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet, 359, 1990-1997.
27. DSCHIETZIG, T., BARTSCH, C., PREGL, R., ZURBRÜGG, H.R., ARMBRUSTER, F.P., RICHTER, C., LAULE, M., ROMEYKE, E., NEUBERT, C., VOELTER, W., BAUMANN, G. & STANGL, K. (2002). Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul. Pept., 110, 33-38.
28. GARDINER, S.M., MARCH, J.E., KEMP, P.A. & BENNETT, T. (2004). Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br. J. Pharmacol., 143, 422-430.
29. GARDINER, S.M., MARCH, J.E., KEMP, P.A., DAVENPORT, A.P. & BENNETT, T. (2001). Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br. J. Pharmacol., 132, 1625-1629.
30. GARDINER, S.M., MARCH, J.E., KEMP, P.A., MAGUIRE, J.J., KUC, R.E., DAVENPORT, A.P. & BENNETT, T. (2006). Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br. J. Pharmacol., 147, 12-21.
31. GENDRON, G., GOBEIL, F.J.R., BELANGER, S., GAGNON, S., REGOLI, D. & D'ORLEANS-JUSTE, P. (2005). Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides, 26, 1468-1474.
32. GENDRON, G., SIMARD, B., GOBEIL, J.F., SIROIS, P., D'ORLÉANS- JUSTE, P. & REGOLI, D. (2004). Human urotensin II enhances plasma extravasation in specific vascular districts in Wistar rats. Can. J. Physiol. Pharmacol., 82, 16-21.
33. GIBSON, A. (1987). Complex effects of Gillichthys urotensin II on rat aortic strips. Br. J. Pharmacol., 91, 205-212.
34. GIBSON, A., WALLACE, P. & BERN, H.A. (1986). Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen. Comp. Endocrinol., 64, 435-439.
35. GIEBING, G., TOLLE, M., JURGENSEN, J., EICHHORST, J., FURKERT, J., BEYERMANN, M., NEUSCHAFER-RUBE, F., ROSENTHAL, W., ZIDEK, W., VAN DER GIET, M. & OKSCHE, A. (2005). Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ. Res., 97, 707-715.
36. GONG, H., WANG, Y.X., ZHU, Y.Z., WANG, W.W., WANG, M.J., YAO, T. & ZHU, Y.C. (2004). Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. J. Appl. Physiol., 97, 2228-2235.
37. GRAY, G.A., JONES, M.R. & SHARIF, I. (2001). Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci., 69, 175-180.
38. HASSAN, G.S., CHOUIALI, F., SAITO, T., HU, F., DOUGLAS, S.A., AO, Z., WILLETTE, R.N., OHLSTEIN, E.H. & GIAID, A. (2003). Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can. J. Physiol. Pharmacol., 81, 125-128.
39. HELLER, J., SCHEPKE, M., NEEF, M., WOITAS, R., RABE, C. & SAUERBRUCH, T. (2002). Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J. Hepatol., 37, 767-772.
40. HERINGLAKE, M., KOX, T., UZUN, O., WILL, B., BAHLMANN, L., KLAUS, S., ELEFTHERIADIS, S., ARMBRUSTER, F.P., FRANZ, N. & KRAATZ, E. (2004). The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul. Pept., 121, 129-136.
41. HILLIER, C., BERRY, C., PETRIE, M.C., O'DWYER, P.J., HAMILTON, C., BROWN, A. & MCMURRAY, J. (2001). Effects of urotensin II in human arteries and veins of varying caliber. Circulation, 103, 1378-1381.
42. HOOD, S.G., WATSON, A.M. & MAY, C.N. (2005). Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. Peptides, 26, 1248-1256.
43. JOHNS, D.G., AO, Z., NASELSKY, D., HEROLD, C.L., MANISCALCO, K., SAROV-BLAT, L., STEPLEWSKI, K., AIYAR, N. & DOUGLAS, S.A. (2004). Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch. Pharmacol., 370, 238-250.
44. JOYAL, D., HUYNH, T., AIYAR, N., GUIDA, B., DOUGLAS, S. & GIAID, A. (2006). Urotensin-II levels in acute coronary syndromes. Int. J. Cardiol., 108, 31-35.
45. KATANO, Y., ISHIHATA, A., AITA, T., OGAKI, T. & HORIE, T. (2000). Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur. J. Pharmacol., 402, 5-7.
46. KOMPA, A.R., THOMAS, W.G., SEE, F., TZANIDIS, A., HANNAN, R.D. & KRUM, H. (2004). Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides, 25, 1783-1788.
47. KRUGER, S., GRAF, J., KUNZ, D., STICKEL, T., MERX, M.W., HANRATH, P. & JANSSENS, U. (2005). Urotensin II in patients with chronic heart failure. Eur. J. Heart Fail., 7, 475-478.
48. LANGHAM, R.G., KELLY, D.J., GOW, R.M., ZHANG, Y., DOWLING, J.K., THOMSON, N.M. & GILBERT, R.E. (2004). Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am. J. Kidney Dis., 44, 826-831.
49. LIM, M., HONISETT, S., SPARKES, C.D., KOMESAROFF, P., KOMPA, A. & KRUM, H. (2004). Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation, 109, 1212-1214.
50. LIN, L., DING, W.H., JIANG, W., ZHANG, Y.G., QI, Y.F., YUAN, W.J. & TANG, C.S. (2004a). Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides, 25, 1977-1984.
51. LIN, Y., MATSUMURA, K., TSUCHIHASHI, T., FUKUHARA, M., FUJII, K. & IIDA, M. (2004b). Role of ERK and Rho kinase pathways in central pressor action of urotensin II. J. Hypertens., 22, 983-988.
52. LIN, Y., TSUCHIHASHI, T., MATSUMURA, K., ABE, I. & IIDA, M. (2003a). Central cardiovascular action of urotensin II in conscious rats. J. Hypertens., 21, 159-165.
53. LIN, Y., TSUCHIHASHI, T., MATSUMURA, K., FUKUHARA, M., OHYA, Y., FUJII, K. & IIDA, M. (2003b). Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens. Res., 26, 839-845.
54. LIU, Q., PONG, S.S., ZENG, Z., ZHANG, Q., HOWARD, A.D., WILLIAMS DL, J.R., DAVIDOFF, M., WANG, R., AUSTIN, C.P., MCDONALD, T.P., BAI, C., GEORGE, S.R., EVANS, J.F. & CASKEY, C.T. (1999). Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun., 266, 174-178.
55. LU, Y., ZOU, C.J., HUANG, D.W. & TANG, C.S. (2002). Cardiovascular effects of urotensin II in different brain areas. Peptides, 23, 1631-1635.
56. MACLEAN, M.R., ALEXANDER, D., STIRRAT, A., GALLAGHER, M., DOUGLAS, S.A., OHLSTEIN, E.H., MORECROFT, I. & POLLAND, K. (2000). Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol., 130, 201-204.
57. MAGUIRE, J.J., KUC, R.E. & DAVENPORT, A.P. (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol., 131, 441-446.
58. MAGUIRE, J.J., KUC, R.E., WILEY, K.E., KLEINZ, M.J. & DAVENPORT, A.P. (2004). Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides, 25, 1767-1774.
59. MATSUSHITA, M., SHICHIRI, M., FUKAI, N., OZAWA, N., YOSHIMOTO, T., TAKASU, N. & HIRATA, Y. (2003). Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology, 144, 1825-1831.
60. MATSUSHITA, M., SHICHIRI, M., IMAI, T., IWASHINA, M., TANAKA, H., TAKASU, N. & HIRATA, Y. (2001). Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens., 19, 2185-2190.
61. MEDAKOVIC, M., CHAN, D.K. & LEDERIS, K. (1975). Pharmacological effects of urotensins. I. Regional vascular effects of urotensins I and II in the rat. Pharmacology, 13, 409-418.
62. MORI, M., SUGO, T., ABE, M., SHIMOMURA, Y., KURIHARA, M., KITADA, C., KIKUCHI, K., SHINTANI, Y., KUROKAWA, T., ONDA, H., NISHIMURA, O. & FUJINO, M. (1999). Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor (GPR14). Biochem. Biophys. Res. Commun., 265, 123-129.
63. NG, L.L., LOKE, I., O'BRIEN, R.J., SQUIRE, I.B. & DAVIES, J.E. (2002). Plasma urotensin in human systolic heart failure. Circulation, 106, 2877-2880.
64. NOTHACKER, H.P., WANG, Z., MCNEILL, A.M., SAITO, Y., MERTEN, S., O'DOWD, B., DUCKLES, S.P. & CIVELLI, O. (1999). Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat. Cell Biol., 1, 383-385.
65. ONAN, D., PIPOLO, L., YANG, E., HANNAN, R.D. & THOMAS, W.G. (2004). Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol., 18, 2344-2354.
66. OVCHARENKO, E., ABASSI, Z., RUBINSTEIN, I., KABALLA, A., HOFFMAN, A. & WINAVER, J. (2006). Renal effects of human urotensin-II in rats with experimental congestive heart failure. Nephrol. Dial. Transplant., 21, 1205-1211.
67. PATACCHINI, R., SANTICIOLI, P., GIULIANI, S., GRIECO, P., NOVELLINO, E., ROVERO, P. & MAGGI, C.A. (2003). Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol., 140, 1155-1158.
68. PAYSANT, J., RUPIN, A., SIMONET, S., FABIANI, J.N. & VERBEUREN, T.J. (2001). Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam. Clin. Pharmacol., 15, 227-231.
69. RAKOWSKI, E., HASSAN, G.S., DHANAK, D., OHLSTEIN, E.H., DOUGLAS, S.A. & GIAID, A. (2005). A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J. Mol. Cell. Cardiol., 39, 785-791.
70. RICHARDS, A.M., NICHOLLS, M.G., LAINCHBURY, J.G., FISHER, S. & YANDLE, T.G. (2002). Plasma urotensin II in heart failure. Lancet, 360, 545-546.
71. RUSSELL, F.D., KEARNS, P., TOTH, I. & MOLENAAR, P. (2004). Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J. Pharmacol. Exp. Ther., 310, 209-214.
72. RUSSELL, F.D., MEYERS, D., GALBRAITH, A.J., BETT, N., TOTH, I., KEARNS, P. & MOLENAAR, P. (2003). Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol., 285, 1576-1581.
73. RUSSELL, F.D., MOLENAAR, P. & O'BRIEN, D.M. (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
74. SAETRUM, O.O., NOTHACKER, H., EHLERT, F.J. & KRAUSE, D.N. (2000). Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol., 406, 265-271.
75. SAUZEAU, V., LE MELLIONNEC, E., BERTOGLIO, J., SCALBERT, E., PACAUD, P. & LOIRAND, G. (2001). Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res., 88, 1102-1104.
76. SHENOUDA, A., DOUGLAS, S.A., OHLSTEIN, E.H. & GIAID, A. (2002). Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J. Histochem. Cytochem., 50, 885-889.
77. SHI, L., DING, W., LI, D., WANG, Z., JIANG, H., ZHANG, J. & TANG, C. (2006). Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis (in press).
78. SILVESTRE, R.A., EGIDO, E.M., HERNANDEZ, R., LEPRINCE, J., CHATENET, D., TOLLEMER, H., CHARTREL, N., VAUDRY, H. & MARCO, J. (2004). Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur. J. Endocrinol., 151, 803-809.
79. SONDERMEIJER, B., KOMP, A., KOMESAROFF, P. & KRUM, H. (2005). Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am. J. Hypertens., 18, 1195-1199.
80. STIRRAT, A., GALLAGHER, M., DOUGLAS, S.A., OHLSTEIN, E.H., BERRY, C., KIRK, A., RICHARDSON, M. & MACLEAN, M.R. (2001). Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. J. Physiol. Heart Circ. Physiol., 280, 925-928.
81. TAMURA, K., OKAZAKI, M., TAMURA, M., ISOZUMI, K., TASAKI, H. & NAKASHIMA, Y. (2003). Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci., 72, 1049-1060.
82. TASAKI, K., HORI, M., OZAKI, H., KARAKI, H. & WAKABAYASHI, I. (2004). Mechanism of human urotensin II-induced contraction in rat aorta. J. Pharmacol. Sci., 94, 376-383.
83. THOMPSON, J.P., WATT, P., SANGHAVI, S., STRUPISH, J.W. & LAMBERT, D.G. (2003). A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth. Analg., 97, 1501-1503.
84. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., MURAKAMI, O., ITO, S., KIKUYA, M., OHKUBO, T., HASHIMOTO, J. & IMAI, Y. (2004). Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides, 25, 1809-1814.
85. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., SATOH, F., ITO, S., KIMURA, Y., SASANO, H. & MURAKAMI, O. (2001). Role of urotensin II in patients on dialysis. Lancet, 358, 810-811.
86. TZANIDIS, A., HANNAN, R.D., THOMAS, W.G., ONAN, D., AUTELITANO, D.J., SEE, F., KELLY, D.J., GILBERT, R.E. & KRUM, H. (2003). Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ. Res., 93, 246-253.
87. VERGURA, R., CAMARDA, V., RIZZI, A., SPAGNOL, M., GUERRINI, R., CALO, G., SALVADORI, S. & REGOLI, D. (2004). Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn Schmiedebergs Arch. Pharmacol., 370, 347-352.
88. WANG, Z.J., SHI, L.B., XIONG, Z.W., ZHANG, L.F., MENG, L., BU, D.F., TANG, C.S. & DING, W.H. (2006). Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides, 27, 858-863.
89. WATANABE, T., PAKALA, R., KATAGIRI, T. & BENEDICT, C.R. (2001a). Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 104, 16-18.
90. WATANABE, T., PAKALA, R., KATAGIRI, T. & BENEDICT, C.R. (2001b). Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J. Hypertens., 19, 2191-2196.
91. WATANABE, T., SUGURO, T., KANOME, T., SAKAMOTO, Y., KODATE, S., HAGIWARA, T., HONGO, S., HIRANO, T., ADACHI, M. & MIYAZAKI, A. (2005). Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension, 46, 738-744.
92. WATSON, A.M., LAMBERT, G.W., SMITH, K.J. & MAY, C.N. (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension, 42, 373-379.
93. WENYI, Z., SUZUKI, S., HIRAI, M., HINOKIO, Y., TANIZAWA, Y., MATSUTANI, A., SATOH, J. & OKA, Y. (2003). Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia, 46, 972-976.
94. WILKINSON, I.B., AFFOLTER, J.T., DE HAAS, S.L., PELLEGRINI, M.P., BOYD, J., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. (2002). High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res., 53, 341-347.
95. WINTER, M.J., ASHWORTH, A., BOND, H., BRIERLEY, M.J., MCCROHAN, C.R. & BALMENT, R.J. (2000). The caudal neurosecretory system: control and function of a novel neuroendocrine system in fish. Biochem. Cell Biol., 783, 193-203.
96. ZHANG, A.Y., CHEN, Y.F., ZHANG, D.X., YI, F.X., QI, J., ANDRADE-GORDON, P., DE GARAVILLA, L., LI, P.L. & ZOU, A.P. (2003). Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am. J. Physiol. Renal Physiol., 285, 792-798.
97. ZHANG, Y., LI, J., CAO, J., CHEN, J., YANG, J., ZHANG, Z., DU, J. & TANG, C. (2002). Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels, 16, 64-68.
98. ZHU, Y.Z., WANG, Z.J., ZHU, Y.C., ZHANG, L., OAKLEY, R.M., CHUNG, C.W., LIM, K.W., LEE, H.S., OZOUX, M.L., LINZ, W., BOHM, M. & KOSTENIS, E. (2004). Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am. J. Physiol. Heart Circ. Physiol., 286, 830-836.
99. ZOU, Y., NAGAI, R. & YAMAZAKI, T. (2001). Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett., 508, 57-60.